8-K: Carisma Therapeutics and OrthoCellix Announce Definitive Merger Agreement to Form Regenerative Cell Therapy Company

Carisma Therapeutics Inc. and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., have entered into a definitive merger agreement to combine, creating a publicly-traded company focused on regenerative cell therapies for orthopedic diseases, with existing Carisma stockholders receiving contingent value rights.

Summary

• Carisma Therapeutics Inc. (Carisma) and OrthoCellix, Inc. (a wholly-owned subsidiary of Ocugen, Inc.) have signed a definitive merger agreement.
• The merger will result in OrthoCellix becoming a wholly-owned subsidiary of Carisma, with the combined entity focusing on OrthoCellix's NeoCart technology for orthopedic diseases.
• Upon closing, Ocugen (as OrthoCellix's sole stockholder) and concurrent investors are expected to own approximately 90.0% of the combined company, while pre-Merger Carisma stockholders will own approximately 10.0%, assuming a $25.0 million concurrent investment.
• OrthoCellix is valued at $135.0 million (adjusted if concurrent investment is less than $25.0 million), and Carisma is valued at $15.0 million (adjusted based on net cash).
• Pre-Merger Carisma stockholders will receive Contingent Value Rights (CVRs) for each outstanding share, entitling them to potential cash payments from the net proceeds of Carisma's legacy asset dispositions (e.g., ModernaTX collaboration) over a two-year period post-closing.
• The combined company will be renamed OrthoCellix, Inc. and trade under the ticker symbol OCLX on the Nasdaq Capital Market.
• The board of directors of the combined company is expected to consist of six members, with five designated by OrthoCellix and one by Carisma.
• The transaction is expected to close in the second half of 2025, subject to stockholder approvals from both companies and SEC registration statement effectiveness.

Sentiment

Score: 7

Explanation: The document announces a strategic merger with clear financial terms and a promising lead product (NeoCart) with RMAT designation and a planned Phase 3 trial. The concurrent financing provides capital for future development. However, the significant dilution for existing Carisma shareholders and the speculative nature of CVRs introduce some negative aspects. The overall tone is positive and forward-looking regarding the new entity's prospects.

Positives

• Creates a publicly-traded company focused on late clinical-stage regenerative cell therapies for orthopedic diseases.
• NeoCart technology has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and concurrence on a single, confirmatory Phase 3 clinical trial.
• NeoCart has the potential to accelerate healing and reduce pain for articular cartilage defects of the knee.
• The combined company aims to complete the Phase 3 trial of NeoCart without additional cost or investment from Ocugen, supported by a concurrent financing.
• Existing Carisma stockholders receive CVRs, offering potential value from Carisma's legacy assets.
• The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Negatives

• Existing Carisma stockholders will own a significantly smaller percentage (approximately 10.0%) of the combined company post-merger.
• The CVRs are contractual rights only, non-transferable (except limited circumstances), not listed on any exchange, and highly speculative, with no assurance of payments.
• Carisma's legacy assets are subject to disposition, and there's no guarantee of Gross Proceeds for CVR payments.
• The transaction is subject to various closing conditions, including stockholder approvals and securing the concurrent investment, which could lead to termination.
• Termination fees apply under certain circumstances, potentially costing Carisma $500,000 or OrthoCellix $750,000 (plus up to $500,000 expenses).

Risks

• Conditions to closing or consummation of the Proposed Transactions may not be satisfied, including failure to timely obtain stockholder approvals for the proposed reverse stock split and merger.
• The proposed concurrent financing may not be completed in a timely manner, or at all.
• Uncertainties exist regarding the timing of the consummation of the Proposed Transactions.
• Risks related to Carisma's continued Nasdaq listing until closing of the Proposed Transactions and the combined company's ability to remain listed following the Closing.
• Uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company's cash resources.
• Risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement.
• The effect of the announcement or pendency of the merger on Carisma's or OrthoCellix's business relationships, operating results and business generally.
• Costs related to the merger and unexpected costs, charges or expenses resulting from the Proposed Transactions.
• The risk that as a result of adjustments to the exchange ratio, OrthoCellix stockholders and Carisma stockholders could own more or less of the combined company than is currently anticipated.
• Risks related to the market price of Carisma's common stock relative to the value suggested by the exchange ratio.
• The uncertainties associated with OrthoCellix's NeoCart portfolio, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials.
• Risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance these product candidates.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market.
• The outcome of any legal proceedings that may be instituted against Carisma, OrthoCellix or any of their respective directors or officers related to the Proposed Transactions.
• The ability of Carisma and OrthoCellix to obtain, maintain, and protect their respective intellectual property rights.
• Competitive responses to the Proposed Transactions.
• Changes in regulatory requirements and government incentives.
• Risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results, legislative, regulatory, political and economic developments, and those uncertainties and factors.
• The risk of involvement in litigation, including securities class action litigation, that could divert the attention of the management of Carisma or the combined company, harm the combined company's business and may not be sufficient for insurance coverage to cover all costs and damages.

Future Outlook

The combined company, to be renamed OrthoCellix, Inc., will focus on advancing OrthoCellix's NeoCart technology, a Phase 3-ready autologous cartilage implant. They anticipate launching a U.S. FDA-endorsed Phase 3 clinical trial for NeoCart by the end of 2025. The concurrent financing is expected to fund the Phase 3 trial without further investment from Ocugen. The transaction is projected to close in the second half of 2025.

Management Comments

• "We believe merging OrthoCellix with Carisma will allow us to create a publicly-traded company focused on the development of NeoCart and provide value for both Ocugen and Carisma stockholders while unlocking true market potential of NeoCart." Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen.
• "We believe NeoCart has tremendous potential to deliver a truly transformative approach to cartilage repair, and we've established OrthoCellix with dedicated resources to bring this revolutionary technology to the patients who desperately need it." Dr. Shankar Musunuri.
• "Carisma evaluated a range of strategic alternatives, and we believe this proposed transaction represents an opportunity to deliver significant value to our stockholders." Steven Kelly, President and Chief Executive Officer, of Carisma.
• "OrthoCellix is strongly positioned with its NeoCart platform, a dedication to developing regenerative cell therapies, and a well-credentialed management team to lead the combined company." Steven Kelly.

Industry Context

This merger represents a strategic shift for Carisma from macrophage engineering for fibrosis and cancer to regenerative cell therapies for orthopedic diseases, aligning with OrthoCellix's focus. The combined entity aims to leverage NeoCart's RMAT designation and Phase 3 readiness to address unmet medical needs in cartilage repair, positioning itself in the growing regenerative medicine and orthopedic markets. The use of a GMP facility established by Ocugen indicates a commitment to efficient development.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions 'risks related to the outcome of any legal proceedings that may be instituted against Carisma, OrthoCellix or any of their respective directors or officers related to the Proposed Transactions.'
• It also mentions 'risk of involvement in litigation, including securities class action litigation, that could divert the attention of the management of Carisma or the combined company, harm the combined company's business and may not be sufficient for insurance coverage to cover all costs and damages.'

Related Party Transactions

• Ocugen, Inc. (Guarantor) is the sole stockholder of OrthoCellix, Inc.
• Ocugen contributed NeoCart Assets to OrthoCellix.
• Ocugen will commit to purchase at least $5.0 million of Carisma Common Stock in the concurrent investment.
• Ocugen (as sole OrthoCellix stockholder) entered into a lock-up agreement for 180 days post-closing.
• Ocugen (as sole OrthoCellix stockholder) entered into a support agreement to vote in favor of the merger.
• Transition Services Agreement and Manufacturing and Supply Agreement to be entered into between Guarantor (Ocugen) and the Company (OrthoCellix).

Stakeholder Impact

• Shareholders (Carisma): Will receive shares in the combined company (approx. 10% ownership) and contingent value rights (CVRs) tied to Carisma's legacy asset monetization. This represents significant dilution but potential upside from CVRs and the new focus.
• Shareholders (Ocugen/OrthoCellix): Ocugen, as the sole stockholder of OrthoCellix, and other concurrent investors will own approximately 90% of the combined company, indicating a strong controlling interest and potential for significant upside from NeoCart.
• Employees: The merger will lead to a new management team for the combined company, with OrthoCellix designating the Parent officers. Carisma's prior research and development activities are winding down, which may impact its existing employees. New equity incentive plans are being adopted for the combined company.
• Customers/Patients: The combined company will focus on developing NeoCart for orthopedic diseases, potentially offering a new treatment option for articular cartilage defects of the knee.
• Creditors: The document mentions Carisma's net cash at closing must be at least negative $1,000,000, and liabilities are considered in the net cash calculation, which could impact creditors.

Next Steps

• Carisma to seek stockholder approval for a reverse stock split and other voting proposals.
• Carisma to file a registration statement on Form S-4 with the SEC to register shares issued in the merger.
• OrthoCellix to obtain stockholder approval for the merger.
• Carisma and OrthoCellix to use commercially reasonable efforts to secure the $25.0 million concurrent investment.
• Ocugen to enter into a securities purchase agreement by August 1, 2025, committing to at least $5.0 million investment.
• Carisma to mail proxy statement to stockholders after S-4 effectiveness.
• Combined company to be renamed OrthoCellix, Inc. and trade under OCLX on Nasdaq.
• Combined company board of directors to consist of six members (five from OrthoCellix, one from Carisma).
• OrthoCellix to designate Parent officers.
• Anticipated launch of NeoCart Phase 3 clinical trial by the end of 2025.
• Carisma to monetize certain legacy assets, with proceeds contributing to CVR payments.
• Company and Guarantor to enter into Transition Services Agreement and Manufacturing and Supply Agreement by July 11, 2025.

Key Dates

Recommendation

Keywords

Merger Agreement, SEC Filing, Carisma Therapeutics, OrthoCellix, Ocugen, NeoCart, Regenerative Cell Therapy, Orthopedic Diseases, Phase 3 Clinical Trial, RMAT Designation, Contingent Value Rights, CVR, Reverse Stock Split, Nasdaq Listing, Biologics License Application, Biopharma, Healthcare, Biotechnology